{
  "thread": {
    "uuid": "602a81ff8585182e038b6b1e82fe3724bef81d98",
    "url": "https://news.china.com/socialgd/10000169/20250814/48721687.html",
    "site_full": "news.china.com",
    "site": "china.com",
    "site_section": "https://news.china.com/international/index.html",
    "site_categories": [],
    "section_title": "国际新闻_新闻频道_中华网",
    "site_title": null,
    "title": "阿尔茨海默症国产新药再遇滑铁卢 审批未通过引发关注_新闻频道_中华网",
    "title_full": "阿尔茨海默症国产新药再遇滑铁卢 审批未通过引发关注_新闻频道_中华网",
    "published": "2025-08-14T03:00:00.000+03:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "CN",
    "main_image": "",
    "performance_score": 0,
    "domain_rank": 2039,
    "domain_rank_updated": "2025-06-03T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "602a81ff8585182e038b6b1e82fe3724bef81d98",
  "url": "https://news.china.com/socialgd/10000169/20250814/48721687.html",
  "ord_in_thread": 0,
  "author": "#5434",
  "published": "2025-08-14T03:00:00.000+03:00",
  "title": "阿尔茨海默症国产新药再遇滑铁卢 审批未通过引发关注_新闻频道_中华网",
  "text": "阿尔茨海默症国产新药再遇滑铁卢 审批未通过引发关注！阿尔茨海默症国产新药甘露特钠再次遭遇挫折。8月12日，国家药监局官网显示，绿谷制药的甘露特钠被下发药品通知件。此次针对甘露特钠的通知并没有相应的审批文号，意味着“九期一”没能获得再注册批准。\n国家药监局下发的通知件有多种含义，既可以是获批通过，也可能是发一个不予通过的通知，主要区别在于是否附带了批号。甘露特钠的药品注册证书已满五年，到期应当由药企再次递交上市申请，由国家药监局审批续签。根据受理号，被下发通知件的正是2024年绿谷递交的甘露特钠胶囊两项补充申请。\n甘露特钠胶囊，俗称“九期一”，是国内首款阿尔茨海默症自主研发的创新药物，2019年11月首次在国内附条件批准上市。自上市以来，“九期一”备受争议。今年4月起，“九期一”历经断货、停工停产等诸多风波，绿谷回应是因为药品注册证到期，同时也开启了与学术界的隔空论战。这一系列事件让外界对这款阿尔茨海默症国产新药的关注度迅速上升。\n“九期一”于2019年11月上市，拿到的是“有条件批准”的批文。这是当时药品审评审批改革中的阶段性做法，如今已经固定为“附条件批准”的审批模式。有条件批准和附条件批准要求相差甚远。现在的“附条件批准”非常规范，要求药品上市后继续完成临床研究，原则上要在4年内换成“完全批准”的批文才行，否则就要退市。但当年的“有条件批准”没有这样严格的时限要求，这才诞生了甘露特钠等一批创新药。",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "chinese",
  "sentiment": "negative",
  "categories": [
    "Health",
    "Science and Technology"
  ],
  "topics": [
    "Health->drug rehabilitation",
    "Health->health treatment and procedure",
    "Science and Technology->biotechnology",
    "Science and Technology->medical research"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": null,
  "webz_reporter": false,
  "external_links": [],
  "external_images": [],
  "internal_images": [],
  "entities": {
    "persons": [],
    "locations": [],
    "organizations": []
  },
  "syndication": {
    "syndicated": null,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "top_news": [],
    "bias": null,
    "source": {
      "type": null,
      "city": null,
      "state": null,
      "country": null,
      "domain_type": null,
      "agency": null,
      "organization_name": null
    }
  },
  "rating": null,
  "crawled": "2025-08-14T10:45:02.277+03:00",
  "updated": "2025-08-14T10:49:27.000+03:00"
}